NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
VL E-GOVERNANCE & IT SOLUTIONS LIMITED APPROVES ALLOTMENT OF 5.34 CRORE WARRANTS, AMOUNTING TO RS. 400.99 CRORE ON A PREFERENTIAL BASIS
Board approved the allotment of 5.34 Crore Fully Convertible Warrants ("Warrants") each…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line…
